News

Chronic Obstructive Pulmonary Disease (COPD) is a progressive, long-term lung condition that can make it hard to breathe. The main cause of COPD is tobacco smoking1; however, other factors can contribute, such as: Indoor and outdoor air pollution1, Workplace exposures1,...

Bedfont® now focuses on supporting clinical research, debuting at the 9th annual Outsourcing in Clinical Trials DACH in Basel. Bedfont® Scientific Limited, a world leader in breath analysis with 50 years of experience manufacturing medical devices, has quietly supported respiratory...

Asthma is a chronic lung condition affecting approximately 339.4 million people worldwide1, and when uncontrolled, it can be quite debilitating in everyday life. Despite modern-day medicine and the availability of effective treatments, approximately 39% of people with asthma remain uncontrolled1....

Bedfont®, a world leader in breath analysis, announces its acquisition of coVita™, building on 16 years of partnership, market knowledge, and established infrastructure to support global expansion. Bedfont® Scientific Limited, a leading MedTech company with 50 years of experience designing...

World leaders in breath analysis will showcase its Gastrolyzer® range at one of the leading international events for digestive health. Bedfont® Scientific Limited, a world leader in breath analysis with 50 years of industry experience, is pleased to attend this...

Smokerlyzer® registration with Medicah S.A.S in Colombia boosts quit-smoking services in the region. Bedfont® Scientific Limited, an innovative MedTech company with nearly 50 years of experience in the breath analysis industry, is pleased to collaborate with Medicah S.A.S through a...